Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.

Trial Profile

Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Sep 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual patient number (1851) as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top